GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -63.69 Billion KRW | -34.05% |
| 2022 | -25.32 Billion KRW | -140.09% |
| 2021 | -6.54 Billion KRW | 23.43% |
| 2020 | -13.63 Billion KRW | -762.51% |
| 2019 | -1.82 Billion KRW | 70.3% |
| 2018 | -9.05 Billion KRW | 72.28% |
| 2017 | -20.33 Billion KRW | -69.02% |
| 2016 | -12.02 Billion KRW | -1108.5% |
| 2015 | -2.5 Billion KRW | 125.98% |
| 2014 | -4.58 Billion KRW | 18.18% |
| 2013 | -5.61 Billion KRW | 12.74% |
| 2012 | -5.74 Billion KRW | -244.59% |
| 2011 | -2.16 Billion KRW | -113.13% |
| 2010 | -4.37 Billion KRW | 81.17% |
| 2009 | -5.44 Billion KRW | 3.17% |
| 2008 | -5.12 Billion KRW | -38.12% |
| 2007 | -2.46 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -6.61 Billion KRW | 86.38% |
| 2024 Q2 | -7.36 Billion KRW | -63.66% |
| 2023 FY | - KRW | -34.05% |
| 2023 Q1 | -1.57 Billion KRW | 88.15% |
| 2023 Q2 | -3.9 Billion KRW | -148.63% |
| 2023 Q3 | -1.27 Billion KRW | 67.39% |
| 2023 Q4 | -7.14 Billion KRW | -460.79% |
| 2022 Q2 | -8.33 Billion KRW | -345.91% |
| 2022 Q3 | -3.07 Billion KRW | 63.12% |
| 2022 FY | - KRW | -140.09% |
| 2022 Q4 | -13.26 Billion KRW | -331.32% |
| 2022 Q1 | -1.87 Billion KRW | 55.02% |
| 2021 Q1 | 87.46 Million KRW | 101.01% |
| 2021 FY | - KRW | 23.43% |
| 2021 Q4 | -4.15 Billion KRW | -45.27% |
| 2021 Q2 | -4.12 Billion KRW | -4816.6% |
| 2021 Q3 | -2.86 Billion KRW | 30.62% |
| 2020 Q4 | -8.63 Billion KRW | -283.29% |
| 2020 FY | - KRW | -762.51% |
| 2020 Q3 | -2.25 Billion KRW | 11.37% |
| 2020 Q2 | -2.54 Billion KRW | -149.94% |
| 2020 Q1 | -1.01 Billion KRW | 3.84% |
| 2019 FY | - KRW | 70.3% |
| 2019 Q1 | 882.01 Million KRW | -46.86% |
| 2019 Q2 | -2.79 Billion KRW | -417.28% |
| 2019 Q3 | 1.02 Billion KRW | 136.49% |
| 2019 Q4 | -1.05 Billion KRW | -203.55% |
| 2018 Q3 | -1.1 Billion KRW | 65.47% |
| 2018 Q4 | 1.65 Billion KRW | 250.05% |
| 2018 Q2 | -3.2 Billion KRW | -17.6% |
| 2018 Q1 | -2.72 Billion KRW | 55.94% |
| 2018 FY | - KRW | 72.28% |
| 2017 Q1 | -4.24 Billion KRW | -64.08% |
| 2017 Q3 | -3.57 Billion KRW | 51.36% |
| 2017 Q4 | -6.18 Billion KRW | -73.13% |
| 2017 FY | - KRW | -69.02% |
| 2017 Q2 | -7.34 Billion KRW | -72.86% |
| 2016 Q4 | -2.58 Billion KRW | 23.98% |
| 2016 FY | - KRW | -1108.5% |
| 2016 Q3 | -3.4 Billion KRW | 29.35% |
| 2016 Q2 | -4.81 Billion KRW | -413.38% |
| 2016 Q1 | -938.64 Million KRW | 30.05% |
| 2015 Q1 | -413.03 Million KRW | 87.36% |
| 2015 Q3 | 3.69 Billion KRW | 667.81% |
| 2015 FY | - KRW | 125.98% |
| 2015 Q4 | -1.34 Billion KRW | -136.27% |
| 2015 Q2 | -651.62 Million KRW | -57.76% |
| 2014 Q4 | -3.26 Billion KRW | -362.56% |
| 2014 FY | - KRW | 18.18% |
| 2014 Q3 | -706.61 Million KRW | -6.89% |
| 2014 Q2 | -661.05 Million KRW | -5071.27% |
| 2014 Q1 | 13.29 Million KRW | -95.61% |
| 2013 Q2 | -2.17 Billion KRW | -1.68% |
| 2013 Q1 | -2.14 Billion KRW | 10.5% |
| 2013 Q3 | -1.55 Billion KRW | 28.5% |
| 2013 Q4 | 303.21 Million KRW | 119.45% |
| 2013 FY | - KRW | 12.74% |
| 2012 FY | - KRW | -244.59% |
| 2012 Q2 | -2.28 Billion KRW | -111.0% |
| 2012 Q3 | -435.25 Million KRW | 80.95% |
| 2012 Q4 | -2.39 Billion KRW | -450.32% |
| 2012 Q1 | -1.08 Billion KRW | 0.0% |
| 2011 Q3 | -254.98 Million KRW | 61.92% |
| 2011 FY | - KRW | -113.13% |
| 2011 Q2 | -669.68 Million KRW | -126.78% |
| 2011 Q1 | -295.29 Million KRW | 0.0% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 FY | - KRW | 81.17% |
| 2010 Q3 | -1.88 Billion KRW | -774.66% |
| 2010 Q2 | -216.01 Million KRW | 50.88% |
| 2010 Q1 | -439.8 Million KRW | 0.0% |
| 2010 Q4 | - KRW | 100.0% |
| 2009 Q2 | -4.4 Billion KRW | -1275.33% |
| 2009 Q3 | -2.3 Billion KRW | 47.68% |
| 2009 Q4 | - KRW | 100.0% |
| 2009 FY | - KRW | 3.17% |
| 2009 Q1 | -320.35 Million KRW | 88.2% |
| 2008 Q3 | -253.71 Million KRW | 77.25% |
| 2008 Q4 | -2.71 Billion KRW | -970.12% |
| 2008 FY | - KRW | -38.12% |
| 2008 Q2 | -1.11 Billion KRW | -55.03% |
| 2008 Q1 | -719.4 Million KRW | 38.17% |
| 2007 Q4 | -1.16 Billion KRW | -77.73% |
| 2007 Q2 | -1.27 Billion KRW | -229.86% |
| 2007 Q3 | -654.63 Million KRW | 48.59% |
| 2007 Q1 | -386.05 Million KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | 506.578% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | 195.298% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 158.008% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | 854.693% |
| Green Cross Corporation | 109.81 Billion KRW | 158.008% |
| Celltrion, Inc. | 897.26 Billion KRW | 107.099% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 103.973% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | 379.663% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | -186.87% |
| Prestige BioPharma Limited | -31.04 Billion KRW | -105.165% |